The Outcome of Severe Aplastic Anemia Children Treated with Reduced Dose of Cyclophosphamide Combined Cyclosporine A.
10.7534/j.issn.1009-2137.2020.01.038
- Author:
Shu-Chun WANG
1
;
Yao ZOU
1
;
Xiao-Ming LIU
1
;
Xiao-Juan CHEN
1
;
Li ZHANG
1
;
Wen-Yu YANG
1
;
Tian-Feng LIU
1
;
Ye GUO
1
;
Yu-Mei CHEN
1
;
Xiao-Fan ZHU
2
Author Information
1. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College，Tianjin 300020, China.
2. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College，Tianjin 300020, China,E-mail: xfzhu@ihcams.ac.cn.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2020;28(1):225-229
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the clinical efficacy and side effects of reduced-dose of cyclophosphamide combined cyclosporine A for severe aplastic anemia(SAA) children.
METHODS:Ten pediatric patients with SAA from January 2008 to May 2012 were enrolled. All the patients were treated with reduced dose of cyclophosphamide combined cyclosporine A. The dose of cyclophosphamide was 30 mg/(kg·d)×4 d, the dose of cyclosporine A gradually increased >15 mg/L accroding to the blood concentration.
RESULTS:The median follow-up time of the 10 pediatric patients was 100 months (6-126 months). Among 10 children with SAA, 4 cases achieved complete response(CR), 3 cases obtained partial response (PR) and the overall response rate was 70%, the remaining 3 cases showed no response (NR). One refractory patient treated by cyclophosphamide was progressed to paroxysmal nocturnal hemoglobinuria(PNH) at 25 months and was dead at 42 months after therapy.
CONCLUSION:The results show that reduced-dose cyclophosphamide (30 mg/kg·d for 4 consecutive days) combinated with CsA (initial dose 4 mg/kg·d, and drugvallery concentration >150 ng/ml) can make 7 of 10 children with severe aplastic anemia achieve complete response or partial response, and this regimen may be the second line regimen selected for some SAA children.
